Skip to main content

Market Overview

Mid-Afternoon Market Update: Dow Up Over 100 Points; Achieve Life Sciences Shares Spike Higher


Toward the end of trading Tuesday, the Dow traded up 0.49 percent to 24,370.33 while the NASDAQ climbed 0.85 percent to 7,596.27 . The S&P also rose, gaining 0.54 percent to 2,731.75 .

Leading and Lagging Sectors

Tuesday afternoon, the energy shares surged 1.1 percent. Meanwhile, top gainers in the sector included NextDecade Corporation (NASDAQ: NEXT) up 10 percent, and Clean Energy Fuels Corp. (NASDAQ: CLNE) up 9 percent.

In trading on Tuesday, telecommunication services shares fell 0.76 percent.

Top Headline

Lennar Corporation (NYSE: LEN) reported better-than-expected results for its fiscal second quarter.

Lennar said it earned $1.58 per share in the quarter on revenue of $5.459 billion versus expectations of 45 cents and $5.1 billion.


Equities Trading UP

TSR, Inc. (NASDAQ: TSRI) shares shot up 37 percent to $8.30 after James Hughes requested TSR pursue a sale of the company.

Shares of Lee Enterprises, Incorporated (NYSE: LEE) got a boost, shooting up 27 percent to $3.05. The provider of local news and information, and a major platform for advertising said it reached an agreement to manage Berkshire Hathaway's newspaper and digital operations in 30 markets.

Achieve Life Sciences, Inc. (NASDAQ: ACHV) shares were also up, gaining 29 percent to $4.90. The clinical-stage pharmaceutical company said its product candidate cytosine, an aid to smoking cessation, realized positive results from a series of drug metabolism. This suggests cytisine may be administered with other medications without the need to modify the dose of the co-administered drug.


Equities Trading DOWN

Gevo, Inc. (NASDAQ: GEVO) shares dropped 18 percent to $8.16 following announcement of $8 million at-the-market common stock offering.

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) were down 15 percent to $3.9177. SELLAS Life Sciences reported a proposed 6.017 million share public offering of common stock.

Achaogen, Inc. (NASDAQ: AKAO) was down, falling around 24 percent to $9.11. Achaogen's tryst with the FDA regarding its anti-bacterial agent plazomicin, as expected, ended with a mixed outcome, just as the FDA panel issued a split verdict on it when it met in May. Achaogen announced Tuesday its Zemdri, the trade name for plazomicin, was greenlighted by the FDA for treating adults with complicated urinary tract infections including pyelonephritis, due to certain Enterobacteriaceae for which there's limited or no alternative treatment option.



In commodity news, oil traded up 3.53 percent to $70.48 while gold traded down 0.46 percent to $1,263.00.

Silver traded down 0.20 percent Tuesday to $16.295, while copper rose 0.10 to $3.0125.


European shares closed mostly higher today. The eurozone’s STOXX 600 gained 0.02 percent, the Spanish Ibex Index rose 0.20 percent, while Italy’s FTSE MIB Index climbed 0.30 percent. Meanwhile the German DAX dropped 0.29 percent, and the French CAC 40 slipped 0.05 percent while U.K. shares rose 0.37 percent.


The S&P Corelogic Case-Shiller home price index increased a seasonally adjusted 0.2 percent in April.

The Conference Board’s consumer confidence index declined to 126.4 in June, versus a revised reading of 128.8 in May. However, economists projected a reading of 128.0.

The Richmond Fed's manufacturing index climbed to 20.00 for June, versus prior reading of 16.00. However, economists were expecting a reading of 15.00.


Related Articles (AKAO + ACHV)

View Comments and Join the Discussion!

Posted-In: Mid-Afternoon Market UpdateNews Eurozone Commodities Global Intraday Update Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at